AstraZeneca posts jump in 3Q earnings on H1N1 vaccine

The pharmaceutical company AstraZeneca reported an increase of 24 per cent in pre-tax profits to $3.4 billion for the third quarter, partly owing to strong sales of its swine flu vaccine.

AstraZeneca said its revenue for the three months ended September was up by more than 5 per cent, while margins jumped 44 per cent.

Cholesterol drug Crestor reported sales of $1.1 billion, representing an increase of 30 per cent.

Sales of Toprol-XL also jumped 110 per cent.



Subscribe to RSS - AstraZeneca